Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective.

Homeopathy. 2010 Oct;99(4):231-42.Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective.

Chikramane PS, Suresh AK, Bellare JR, Kane SG. Department of Chemical Engineering, Indian Institute of Technology, Bombay, Adi Shankaracharya Marg, Powai, Mumbai, Maharashtra, India.

Comment in:

Homeopathy. 2010 Oct;99(4):229-30. Abstract Homeopathy is controversial because medicines in high potencies such as 30c and 200c involve huge dilution factors (10⁶⁰ and 10⁴⁰⁰ respectively) which are many orders of magnitude greater than Avogadro's number, so that theoretically there should be no measurable remnants of the starting materials. No hypothesis which predicts the retention of properties of starting materials has been proposed nor has any physical entity been shown to exist in these high potency medicines. Using market samples of metal-derived medicines from reputable manufacturers, we have demonstrated for the first time by Transmission Electron Microscopy (TEM), electron diffraction and chemical analysis by Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES), the presence of physical entities in these extreme dilutions, in the form of nanoparticles of the starting metals and their aggregates.

Copyright © 2010 The Faculty of Homeopathy. Published by Elsevier Ltd. All rights reserved.

Read more: http://www.cbc.ca/consumer/story/2011/01/14/f-homeopathy-naturopathic-marketplace.html#socialcomments#ixzz1B8T9HgtE

#homeopathy Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (HOMDEP-MENOP Study): A Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial

RESEARCH ARTICLE #homeopathy Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (HOMDEP-MENOP Study): A Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial Emma del Carmen Macías-Cortés1,2*, Lidia Llanes-González3, Leopoldo Aguilar-Faisal1, Juan Asbun-Bojalil1 1 División de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Distrito Federal, México, 2 Consulta Externa de Homeopatía, Hospital Juárez de México, Secretaría de Salud, Distrito Federal, México, 3 Unidad de Salud Mental, Hospital Juárez de México, Secretaría de Salud, Distrito Federal, México * ecmc2008@hotmail.es Abstract Background Perimenopausal period refers to the interval when women's menstrual cycles become irreg- ular and is characterized by an increased risk of depression. Use of homeopathy to treat de- pression is widespread but there is a lack of clinical trials about its efficacy in depression in peri- and postmenopausal women. The aim of this study was to assess efficacy and safety of individualized homeopathic treatment versus placebo and fluoxetine versus placebo in peri- and postmenopausal women with moderate to severe depression. Methods/Design A randomized, placebo-controlled, double-blind, double-dummy, superiority, three-arm trial with a 6 week follow-up study was conducted. The study was performed in a public research hospital in Mexico City in the outpatient service of homeopathy. One hundred thirty-three peri- and postmenopausal women diagnosed with major depression according to DSM-IV (moderate to severe intensity) were included. The outcomes were: change in the mean total score among groups on the 17-item Hamilton Rating Scale for Depression, Beck Depres- sion Inventory and Greene Scale, after 6 weeks of treatment, response and remission rates, and safety. Efficacy data were analyzed in the intention-to-treat population (ANOVA with Bonferroni post-hoc test). PLOS ONE | DOI:10.1371/journal.pone.0118440 March 13, 2015 1/24 OPENACCESS Citation: Macías-Cortés EdC, Llanes-González L, Aguilar-Faisal L, Asbun-Bojalil J (2015) Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (HOMDEP-MENOP Study): A Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial. PLoS ONE 10(3): e0118440. doi:10.1371/ journal.pone.0118440 Academic Editor: Yiru Fang, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, CHINA Received: September 18, 2014 Accepted: January 13, 2015 Published: March 13, 2015 Copyright: © 2015 Macías-Cortés et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Data are available upon request to the Research and Ethics Committee of National Homeopathic Hospital, Mexico City [Dr. Gustavo Aguilar-Velázquez ( gav5799@gmail.com

Results After a 6-week treatment, homeopathic group was more effective than placebo by 5 points in Hamilton Scale. Response rate was 54.5% and remission rate, 15.9%. There was a sig- nificant difference among groups in response rate definition only, but not in remission rate. Fluoxetine-placebo difference was 3.2 points. No differences were observed among groups in the Beck Depression Inventory. Homeopathic group was superior to placebo in Greene Climacteric Scale (8.6 points). Fluoxetine was not different from placebo in Greene Climac- teric Scale. Conclusion Homeopathy and fluoxetine are effective and safe antidepressants for climacteric women. Homeopathy and fluoxetine were significantly different from placebo in response definition only. Homeopathy, but not fluoxetine, improves menopausal symptoms scored by Greene Climacteric Scale. Trial Registration ClinicalTrials.gov NCT01635218 Protocol Publication http://www.trialsjournal.com/content/14/1/105 . https://www.hri-research.org/wp-content/uploads/2015/03/Mac%C3%ADas-Cort%C3%A9s-2015-Depression-menopause.pdf

#choosehomeopathy

Congratulations, Homeopathy! Homeopathy is now officially a regulated health profession in Ontario under the Homeopathy Act, April 1, 2015!

Homeopathic remedy Lycopodium Clavatum offers new hope to cancer sufferers: Study

http://www.naturalnews.com/041501_lycopodium_clavatum_cancer_treatment_homeopathic_remedy.html

NaturalNews) One of the most exciting developments in the war on cancer has just been published in the Journal of Acupuncture and Meridian Studies, where new research shows that the homeopathic remedy, Lycopodium Clavatum (a spore bearing plant from the clubmoss family), has an anti-cancer effect on infected cells while protecting normal blood cells.

The report by the Boiron Laboratory in France and the University of Kalyani in India reveals that highly diluted Lycopodium Clavatum remedies (LC-5C and LC-15C) are capable of inducing 'apoptosis' (cellular death) in cervical cancer cells, signifying their possible use as a supportive medicine in cancer therapy.

The $200 billion dollar per year cancer industry is desperate to convince you that chemotherapy, radiation, toxic drugs and surgery are the only proven treatments for the disease, faced as it is today, with rising demand for complementary and alternative cancer medicines.

Not the first time: Other homeopathic remedies fight cancer too

This isn't the first time that a homeopathic remedy has been found to be effective against cancer. Two previous studies have produced similarly exciting results. Frenkel, M. et al. (2010) used ultra-diluted remedies of Phytolacca, Carcinosin, Conium, and Thuja on breast cancer cells and witnessed a deactivation of the cancer in a process called cytotoxicity. Another team, led by Toliopoulos IK, Simos Y, Bougiouklis D and Oikonomidis S (2013), discovered that certain homeopathic complexes were able to stimulate the anti-cancer activity of Natural Killer Cells (part of our immune system) in cancer patients.

With North America holding the second highest incidence rate of cancer in the world, closely followed by Western Europe, the discovery delivers the prospect of an existing, legal and affordable alternative to conventional treatments.

Dr Alexander Tournier, Executive Director of the London-based Homeopathy Research Institute (http://www.homeoinst.org) confirmed the validity of the Boiron/Kalyani report, stating:

"This study is very significant, performed by a well trained team with access to modern molecular biology techniques and with the support of Boiron - a leading homeopathic manufacturer worldwide - thus ensuring that the homeopathy part of the experiment is taken care of correctly."

Lycopodium Clavatum could work against other types of cancer

Although cervical cancer cells were used in the study, the findings suggest that Lycopodium Clavatum could help fight other types of cancer. Dr Tournier adds:

"These results found on [cervical] cells are potentially generalisable to other cancer cell lines, although the tests would have to be done.

"The fact that homeopathic medicines were shown to be effective at selectively killing cancer cells warrants further research, and offers the possibility that homeopathy could be useful for a wide variety of cancer patients in the future."

With Lycopodium Clavatum being widely available to purchase online, it could be tempting for cancer sufferers to self-medicate. However, this would be inadvisable until further research has confirmed its safety and efficacy in patients. Dr Tournier adds:

"Lycopodium is already available to the general public. It would be very easy to purchase from a homeopathic pharmacy. However, I would not recommend taking Lycopodium for cancer, even for cervical cancer. This study does not provide evidence that the homeopathic remedy will be effective in cancer patients. More research is required before such a homeopathic medicine can be used routinely in cancer treatment."

It is nevertheless, still possible to find experienced doctors who treat cancer patients using homeopathy with a high success rate. One of these is Dr. Spinedi's team at the Clinica Santa Croce (http://www.omeopatia.clinicasantacroce.ch) in Switzerland, who use many remedies, carefully selected for the particular complaint and circumstances of each patient.